Biocon Biologics takes over Viatris' biosimilar biz in over 70 countries

Biocon Biologics on Wednesday said it has completed the integration of the acquired biosimilars business from Viatris Inc in over 70 countries in emerging markets effective July 1, 2023, increasing the scale and scope of its business. Following the deal closure in November 2022, this marks the first wave of countries where Viatris' operations have fully transitioned to Biocon Biologics, the company said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fC3Mp2c
via IFTTT